IMPACT OF COADMINISTRATION WITHOUT OR WITH FOOD ON THE 96-WEEK EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HBV PATIENTS SWITCHED FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) TO TAF

被引：0

作者：

Kao, Jia-Horng ^{[1
]}

Chuang, Wan-Long ^{[2
]}

Chen, Chi-Yi ^{[3
]}

Ahn, Sang Hoon ^{[4
]}

Fung, Scott K. ^{[5
]}

Elkhashab, Magdy ^{[6
]}

Hann, Hie-Won L. ^{[7
]}

Ravendhran, Natarajan ^{[8
]}

Nguyen, Tuan T. ^{[9
]}

Tan, Susanna ^{[10
]}

Flaherty, John F. ^{[10
]}

Gagger, Anuj ^{[10
]}

Gao, Bing ^{[10
]}

Brainard, Diana M. ^{[10
]}

Phan, Charles G. ^{[11
]}

Lim, Young-Suk ^{[12
]}

Ferret, Maria Asuncion Buti ^{[13
]}

Lampertico, Pietro ^{[14
]}

机构：

[1] Natl Taiwan Univ Hosp, Dept Internal Med, Div Gastroenterol, Taipei, Taiwan

[2] Kaohsiung Med Univ, Kaohsiung Med Univ Hosp, Hepatobiliary Div, Dept Internal Med, Kaohsiung, Taiwan

[3] Chia Yi Christian Hosp, Dept Internal Med, Chiayi, Taiwan

[4] Severance Hosp, Yonsei Liver Ctr, Seoul, South Korea

[5] Univ Toronto, Toronto, ON, Canada

[6] Toronto Liver Ctr, Res, Toronto, ON, Canada

[7] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA

[8] Digest Dis Associates PA, Wyomissing, PA USA

[9] T Nguyen Res & Educ Inc, San Diego, CA USA

[10] Gilead Sci Inc, 353 Lakeside Dr, Foster City, CA 94404 USA

[11] Mem Hermann Sugar Land, Sugar Land, TX USA

[12] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Gastroenterol,Liver Ctr, Seoul, South Korea

[13] Hosp Univ Vall dHebron, Dept Internal Med, Liver Unit, Barcelona, Spain

[14] Fdn Irccs Ca Granda Osped Maggiore Policlin, CRC AM & A Migliavacca Ctr Liver Dis, Div Gastroenterol & Hepatol, Milan, Italy

来源：

HEPATOLOGY | 2020年 / 72卷

关键词：

D O I：

暂无

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

795

引用

页码：484A / 484A

页数：1

共 50 条

[31] The Effect of Switching from Tenofovir Disoproxil Fumarate (TDF) to Tenofovir Alafenamide (TAF) on Liver Enzymes, Glucose, and Lipid Profile [J].

Squillace, Nicola ;

Ricci, Elena ;

Menzaghi, Barbara ;

De Socio, Giuseppe Vittorio ;

Passerini, Simone ;

Martinelli, Canio ;

Mameli, Maria Sabrina ;

Maggi, Paolo ;

Falasca, Katia ;

Cordier, Laura ;

Celesia, Benedetto Maurizio ;

Salomoni, Elena ;

Di Biagio, Antonio ;

Pellicano, Giovanni Francesco ;

Bonfanti, Paolo .

DRUG DESIGN DEVELOPMENT AND THERAPY, 2020, 14 :5515-5520

[32] A phase 3 study of tenofovir alafenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) in patients with HBeAg-negative, chronic hepatitis B (CHB): Week 48 efficacy and safety results [J].

Cheng, W. ;

Pianko, S. ;

Thompson, A. ;

Buti, M. ;

Gane, E. ;

Seto, W. K. ;

Chan, H. L. Y. ;

Chuang, W-L ;

Stepanova, T. ;

Hui, A-J ;

Lim, Y-S ;

Mehta, R. ;

Janssen, H. ;

Acharya, S. K. ;

Flaherty, J. F. ;

Massetto, B. ;

Cathcart, A. ;

Dinh, P. ;

Subramanian, G. M. ;

Mchutchison, J. G. ;

Pan, C. ;

Brunetto, M. ;

Izumi, N. ;

Marcellin, P. .

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 :68-69

[33] EFFICACY AND SAFETY OF TENOFOVIR ALAFENAMIDE (TAF) VS TENOFOVIR DISOPROXIL FUMARATE (TDF) IN EAST ASIAN CHRONIC HEPATITIS B PATIENTS FOLLOWING 5-YEARS OF TREATMENT [J].

Wong, Grace Lai Hung ;

Gane, Edward ;

Pan, Calvin ;

Lim, Young-Suk ;

Fung, Scott ;

Izumi, Namiki ;

Ma, Mang ;

Chan, Carol Yee Kwan ;

Shalimar, Dr ;

Buti, Maria .

GUT, 2021, 70 :A76-A76

[34] WEEK 96 EFFICACY AND SAFETY RESULTS OF TENOFOVIR ALAFENAMIDE (TAF) COMPARING TO TENOFOVIR DISOPROXIL FUMARATE (TDF) IN CHRONIC HEPATITIS B (CHB), HBEAG-NEGATIVE, CHRONIC HEPATITIS B PATIENTS: A GLOBAL PHASE 3 STUDY [J].

Brunetto, Maurizia Rossana ;

Lim, Young-Suk ;

Gane, Edward ;

Seto, Wai-Kay ;

Osipenko, Marina ;

Ahn, Sang Hoon ;

Janssen, Harry L. ;

Shukla, Akash ;

Chuang, Wan-Long ;

Trinh, Huy N. ;

Celen, Mustafa ;

Flaherty, John F. ;

Chan, Alain ;

Lau, Audrey ;

Gaggar, Anuj ;

Suri, Vithika ;

Subramanian, Mani ;

Pan, Calvin Q. ;

Izumi, Namiki ;

Marcellin, Patrick ;

Chan, Henry L. ;

Buti, Maria .

GASTROENTEROLOGY, 2017, 152 (05) :S1086-S1086

[35] Three Year Efficacy and Safety of Tenofovir Alafenamide (TAF) Compared to Tenofovir Disoproxil Fumarate (TDF) in Hbeag-Negative and Hbeag-Positive Patients with Chronic Hepatitis B [J].

Chan, Henry Lik Yuen ;

Lim, Young-Suk ;

Seto, Wai Kay Walter ;

Agarwal, Kosh ;

Brunetto, Maurizia R. ;

Janssen, Harry L. A. ;

Caruntu, Florin ;

Stepanova, Tatjana ;

Tsang, Owen ;

Yatsuhashi, Hiroshi ;

Tak, Won Young ;

Chen, Chi-Yi ;

Celen, Mustafa ;

Suri, Vithika ;

Flaherty, John F. ;

Lin, Lanjia ;

Cathcart, Andrea ;

Gaggar, Anuj ;

Pan, Calvin Q. ;

Shalimar ;

Buti, Maria .

HEPATOLOGY, 2018, 68 :227A-228A

[36] Long-Term (96-Week) Efficacy and Safety After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in HIV-Infected, Virologically Suppressed Adults [J].

Raffi, Francois ;

Orkin, Chloe ;

Clarke, Amanda ;

Slama, Laurence ;

Gallant, Joel ;

Daar, Eric ;

Henry, Keith ;

Santana-Bagur, Jorge ;

Stein, David K. ;

Bellos, Nicholaos ;

Scarsella, Anthony ;

Yan, Mingjin ;

Abram, Michael E. ;

Cheng, Andrew ;

Rhee, Martin S. .

JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2017, 75 (02) :226-231

[37] Safety and efficacy at 1 year after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in chronic HBV patients with risk factors for TDF use [J].

Janssen, H. ;

Gane, E. ;

Seto, W-K ;

Caruntu, F. A. ;

Kim, H. J. ;

Abdurakhmanov, D. ;

Nishiguchi, S. ;

Horban, A. ;

Bae, H. ;

Mo, S. ;

Suri, V. ;

Gaggar, A. ;

Flaherty, J. ;

Kao, J-H ;

Brunetto, M. ;

Ferret, M. B. .

JOURNAL OF VIRAL HEPATITIS, 2018, 25 :27-27

[38] 96-Week Treatment of Tenofovir Amibufenamide and Tenofovir Disoproxil Fumarate in Chronic Hepatitis B Patients [J].

Liu, Zhihong ;

Jin, Qinglong ;

Zhang, Yuexin ;

Gong, Guozhong ;

Wu, Guicheng ;

Yao, Lvfeng ;

Wen, Xiaofeng ;

Gao, Zhiliang ;

Huang, Yan ;

Yang, Daokun ;

Chen, Enqiang ;

Mao, Qing ;

Lin, Shide ;

Shang, Jia ;

Gong, Huanyu ;

Zhong, Lihua ;

Yin, Huafa ;

Wang, Fengmei ;

Hu, Peng ;

Wu, Qiong ;

Pan, Chao ;

Jia, Wen ;

Li, Chuan ;

Sun, Chang'an ;

Niu, Junqi ;

Hou, Jinlin .

JOURNAL OF CLINICAL AND TRANSLATIONAL HEPATOLOGY, 2023, 11 (03) :649-660

[39] Safety and Efficacy at 1 Year after Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in Chronic HBV Patients with Risk Factors for TDF Use [J].

Gane, Edward ;

Seto, Wai Kay ;

Janssen, Harry L. A. ;

Caruntu, Florin A. ;

Kim, Hyung Joon ;

Abdurakhmanov, Dzhamal ;

Nishiguchi, Shuhei ;

Horban, Andrzej ;

Bae, Ho ;

Flaherty, John F. ;

Gaggar, Anuj ;

Suri, Vithika ;

Oberle, Corinna ;

Mo, Shuyuan ;

Subramanian, G. Mani ;

Kao, Jia-Horng ;

Brunetto, Maurizia ;

Buti, Maria .

SWISS MEDICAL WEEKLY, 2018, 148 :26S-26S

[40] SWITCHING FROM TENOFOVIR DISOPROXIL FUMARATE (TDF) AND/OR OTHER ORAL ANTIVIRALS (OAVS) TO TENOFOVIR ALAFENAMIDE (TAF) IN VIRALLY SUPPRESSED CHRONIC HEPATITIS B (CHB) PATIENTS WITH HEPATIC IMPAIRMENT: FINAL 2-YEAR EFFICACY AND SAFETY RESULTS FROM A PHASE 2 [J].

Lim, Young-Suk ;

Lin, Chun-Yen ;

Heo, Jeong ;

Bae, Ho ;

Chuang, Wan-Long ;

Yin, Tak ;

Tsang, Owen ;

Fournier, Claire ;

Hui, Aric Josun ;

Trinh, Huy ;

Chan, Carol Yee Kwan ;

Tan, Susanna K. ;

Zhao, Yang ;

Flaherty, John F. ;

Suri, Vithika ;

Gaggar, Anuj ;

Brainard, Dianna M. ;

Ryder, Stephen ;

La Janssen, Harry .

GUT, 2021, 70 :A77-A77

← 1 2 3 4 5 →